PURPOSE: To assess the prognostic value of histological parameters in patients with clinical stage I nonseminomatous germ cell tumors (NSGCTs) undergoing active surveillance post-orchiectomy. METHODS: Prognoses and recurrence patterns were investigated in 78 patients with CSI NSGCT who underwent orchiectomy. Immediately following orchiectomy, patients participated in active surveillance between 1999 and 2013 at Sun Yat-sen University Cancer Center, Guangzhou, China. RESULTS: 23.1 % of the 78 investigated patients with CSI NSGCT relapsed, within a median time of 5.6 months It was determined using multivariate analysis that lymph vascular invasion (LVI) (OR 6.521; 95 % CI 1.872-22.721; p = 0.003) and the predominant presence of yolk sac tumor (greater than 50 %) (OR 3.537; 95 % CI 1.076-11.628; p = 0.038) independently correlated with relapse-free survival (RFS). Patients were categorized accordingly into three risk groups: low risk [<50 % presence of yolk sac tumor and LVI (-); n = 41], intermediate risk [50 % or greater presence of yolk sac tumor and LVI (+); n = 29], and high risk [50 % or greater presence of yolk sac tumor and LVI (+); n = 8]. Relapse rates of the low-risk, intermediate-risk, and high-risk groups were 7.3, 31.0, and 75.0 %, respectively. CONCLUSIONS: LVI and a predominant presence of yolk sac tumor are crucial risk factors for relapse of CSI NSGCT. For patients without either of these risk factors, active surveillance post-orchiectomy is a safe and effective approach for the initial management of CSI NSGCT.
PURPOSE: To assess the prognostic value of histological parameters in patients with clinical stage I nonseminomatous germ cell tumors (NSGCTs) undergoing active surveillance post-orchiectomy. METHODS: Prognoses and recurrence patterns were investigated in 78 patients with CSI NSGCT who underwent orchiectomy. Immediately following orchiectomy, patients participated in active surveillance between 1999 and 2013 at Sun Yat-sen University Cancer Center, Guangzhou, China. RESULTS: 23.1 % of the 78 investigated patients with CSI NSGCT relapsed, within a median time of 5.6 months It was determined using multivariate analysis that lymph vascular invasion (LVI) (OR 6.521; 95 % CI 1.872-22.721; p = 0.003) and the predominant presence of yolk sac tumor (greater than 50 %) (OR 3.537; 95 % CI 1.076-11.628; p = 0.038) independently correlated with relapse-free survival (RFS). Patients were categorized accordingly into three risk groups: low risk [<50 % presence of yolk sac tumor and LVI (-); n = 41], intermediate risk [50 % or greater presence of yolk sac tumor and LVI (+); n = 29], and high risk [50 % or greater presence of yolk sac tumor and LVI (+); n = 8]. Relapse rates of the low-risk, intermediate-risk, and high-risk groups were 7.3, 31.0, and 75.0 %, respectively. CONCLUSIONS: LVI and a predominant presence of yolk sac tumor are crucial risk factors for relapse of CSI NSGCT. For patients without either of these risk factors, active surveillance post-orchiectomy is a safe and effective approach for the initial management of CSI NSGCT.
Authors: Jeetesh M Bhardwa; Tom Powles; Dan Berney; Suhail Baithun; Vinod H Nargund; R Tim D Oliver Journal: BJU Int Date: 2005-10 Impact factor: 5.588
Authors: Craig R Nichols; Bruce Roth; Peter Albers; Lawrence H Einhorn; Richard Foster; Siamak Daneshmand; Michael Jewett; Padraig Warde; Christopher J Sweeney; Clair Beard; Tom Powles; Scott Tyldesley; Alan So; Christopher Porter; Semra Olgac; Karim Fizazi; Brandon Hayes-Lattin; Peter Grimison; Guy Toner; Richard Cathomas; Carsten Bokemeyer; Christian Kollmannsberger Journal: J Clin Oncol Date: 2013-09-03 Impact factor: 44.544
Authors: Janine Nuver; Andries J Smit; Jan van der Meer; Maarten P van den Berg; Winette T A van der Graaf; Martin T Meinardi; Dirk Th Sleijfer; Harald J Hoekstra; Anne I van Gessel; Arie M van Roon; Jourik A Gietema Journal: J Clin Oncol Date: 2005-11-21 Impact factor: 44.544
Authors: B M Colls; V J Harvey; L Skelton; C M Frampton; P I Thompson; M Bennett; D J Perez; P J Dady; G V Forgeson; I C Kennedy Journal: BJU Int Date: 1999-01 Impact factor: 5.588
Authors: Qiwei Yang; Colleen M Kiernan; Yufeng Tian; Helen R Salwen; Alexandre Chlenski; Babette A Brumback; Wendy B London; Susan L Cohn Journal: Clin Cancer Res Date: 2007-06-01 Impact factor: 12.531
Authors: Friedemann Zengerling; Dirk Beyersdorff; Jonas Busch; Julia Heinzelbecker; David Pfister; Christian Ruf; Christian Winter; Peter Albers; Sabine Kliesch; Stefanie Schmidt Journal: World J Urol Date: 2022-07-29 Impact factor: 3.661
Authors: Joost M Blok; Ilse Pluim; Gedske Daugaard; Thomas Wagner; Katarzyna Jóźwiak; Erica A Wilthagen; Leendert H J Looijenga; Richard P Meijer; J L H Ruud Bosch; Simon Horenblas Journal: BJU Int Date: 2020-01-08 Impact factor: 5.588